02
Independent commentary on peptide and research-compound science — drawn from the literature, the lab, and the researchers working with these compounds.
Featured
Retatrutide and Cardiovascular Risk Biomarkers: What the Latest Data Shows
A new analysis in Diabetes, Obesity & Metabolism reports biomarker improvements across cardiac-related measures in adults with obesity, with or without type 2 diabetes.
Key Finding Improvements in cardiovascular risk biomarkers were observed in both diabetic and non-diabetic groups over the treatment period — but the results are biomarker-level, not proof of long-term cardiovascular benefit.
Latest7 items
03
GLP-1 Receptor Agonists and Idiopathic Intracranial Hypertension: A Systematic Review
A systematic review examined GLP-1 receptor agonists in idiopathic intracranial hypertension — a signal that incretin research is expanding beyond metabolic outcomes.
04
What a Certificate of Analysis Does — and Does Not — Prove
A COA is a snapshot of what one laboratory measured on one sample. Understanding its limits is as important as reading its numbers.
05
Why Batch-Specific Testing Matters More Than Generic Certificates
Two identical-looking vials can come from different batches — and different batches can differ in ways a generic certificate will never reveal.
06
NAD+ Research Is Widening — and So Are the Questions
A batch of new NAD+ papers spans redox biology, cancer metabolism, and sirtuin signaling. The breadth is a reminder that NAD+ is a fundamental biochemistry topic, not just a supplement.
07
GHK-Cu: Human Evidence vs. Preclinical Claims
GHK-Cu is among the most widely discussed copper peptides. The interesting question is which of its effects are backed by human evidence and which remain preclinical.